Cilostazol reduces PAC-1 expression on platelets in ischemic stroke

Area of Science:

• Cardiovascular Medicine
• Neurology
• Pharmacology

Background:

• Cilostazol, a phosphodiesterase III inhibitor, is recognized for its antiplatelet properties and potential to inhibit atherosclerosis progression in ischemic stroke.
• Activated platelets play a crucial role in the pathophysiology of acute ischemic stroke.

Purpose of the Study:

• To investigate the combined effects of cilostazol and aspirin on P-selectin and PAC-1 expression in activated platelets in patients with acute ischemic stroke.
• To evaluate the clinical progression in patients receiving aspirin alone versus aspirin plus cilostazol.

Main Methods:

• A study involving 70 patients with acute ischemic stroke within 72 hours of symptom onset.
• Patients were divided into two groups: aspirin alone (100 mg/day) and aspirin (100 mg/day) plus cilostazol (200 mg/day).
• Measurements of P-selectin and PAC-1 expression on activated platelets and the National Institutes of Health Stroke Scale (NIHSS) were performed at baseline and after 5 days.

Main Results:

• Combined aspirin and cilostazol significantly reduced PAC-1 expression on activated platelets compared to baseline (61.0% vs. 70.9%, p=0.008).
• Aspirin alone did not significantly alter PAC-1 expression compared to baseline.
• No significant differences in P-selectin expression or clinical progression (NIHSS scores) were observed between the two groups.

Conclusions:

• The combination of aspirin and cilostazol effectively reduces PAC-1 activity on activated platelets in acute ischemic stroke.
• Despite the observed effect on platelet activation markers, the combined regimen did not demonstrate superior clinical outcomes compared to aspirin monotherapy in the acute phase.
• Further research is warranted to explore the potential clinical benefits of cilostazol in managing acute ischemic stroke.